David Malcom Rodman - 11 Mar 2024 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Medical Officer
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
11 Mar 2024
Net transactions value
+$9,565
Form type
4
Filing time
13 Mar 2024, 17:35:35 UTC
Previous filing
15 Feb 2024
Next filing
15 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Options Exercise $2,709 +5,017 +11% $0.5400* 49,283 11 Mar 2024 Direct
transaction MLYS Common Stock Options Exercise $6,856 +6,348 +13% $1.08* 55,631 12 Mar 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Options Exercise $0 -5,017 -9.1% $0.000000 50,173 11 Mar 2024 Common Stock 5,017 $0.5400 Direct F1, F2
transaction MLYS Stock Option Options Exercise $0 -6,348 -2.9% $0.000000 209,503 12 Mar 2024 Common Stock 6,348 $1.08 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.
F2 The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.
F3 Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.
F4 The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.